Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetically engineered myeloma cell vaccine.

Siguo Hao1, Tim Chan, Jim Xiang

  • 1Sakatoon Cancer Centre, University of Saskatchewan, Saskatoon, Canada.

Methods in Molecular Medicine
|June 22, 2005
PubMed
Summary

Engineered myeloma cells expressing CD40 ligand (CD40L) were created to test cancer vaccine strategies. These modified tumor cells lost their ability to form tumors and induced protective immunity against cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Haploidentical donor versus double-unit cord blood transplantation in hematologic malignancies: comparative survival and graft-versus-host disease outcomes from a decade of real-world experience.

BMC cancer·2026
Same author

Pre-Transplant MRD Negativity and Age Under 40 Predict Superior Long-Term Survival in Relapsed/Refractory B-ALL After CAR-T Therapy Bridging to Haploidentical HSCT: A Multicenter Retrospective Study With 6-Year Follow-Up.

American journal of hematology·2026
Same author

TGF-β Regulates CD8<sup>+</sup> T Cell Memory by Triggering mTORC1<sup>Weak</sup>-Mediated Activation of the Transcriptional FOXO1-TCF1-Eomes and Metabolic AMPK-ULK1-ATG7 Pathways.

Cells·2026
Same author

Nucleoplasmic ZNF467 condensates boost hematopoietic stem cell engraftment via ICAM1-mediated mechanical reprogramming.

Blood·2026
Same author

Safety and Efficacy of Cyclophosphamide With Dual Mecapegfilgrastim and On-Demand Plerixafor for Salvage Mobilization in Patients With Initial Mobilization Failure: A Retrospective Cohort.

Journal of clinical apheresis·2026
Same author

Safety and efficacy of a pre-phase with dexamethasone followed by fractionated R-CHOP in diffuse large B-cell lymphoma patients with gastrointestinal involvement at diagnosis.

Annals of hematology·2026

Area of Science:

  • Immunology
  • Cancer Research
  • Molecular Biology

Background:

  • Engineered tumor cells expressing immunogenes are utilized in cancer vaccines.
  • These vaccines aim to stimulate antitumor immunity and elucidate immune mechanisms.
  • CD40 ligand (CD40L) is a key molecule in immune system activation.

Purpose of the Study:

  • To describe the cloning of mouse CD40L cDNA and construction of the pcDNA-CD40L expression vector.
  • To detail the generation of J558/CD40L myeloma cells engineered to express CD40L.
  • To evaluate the tumorigenicity and immunogenicity of these engineered cells.

Main Methods:

  • Cloning of mouse CD40L cDNA.
  • Construction of the pcDNA-CD40L expression vector.
  • Generation and characterization of J558/CD40L engineered myeloma cells.
  • Assessment of tumor growth and immune response in syngeneic mice.

Main Results:

  • Successful cloning of CD40L cDNA and creation of the pcDNA-CD40L vector.
  • Generation of J558/CD40L cells expressing CD40 ligand.
  • Demonstrated loss of tumorigenicity in J558/CD40L cells in vivo.
  • Inoculation with J558/CD40L cells conferred protective immunity against wild-type J558 tumors.

Conclusions:

  • Engineered J558/CD40L tumor cells are non-tumorigenic.
  • These engineered cells can induce protective antitumor immunity.
  • This approach holds potential for cancer vaccine development and immunotherapy research.

Related Experiment Videos